The injectable form would only be used during pregnancy if there is a clear medical need (such as a severe deficiency or inability to take oral vitamins)
Important Research Limitations Approval for one rare-disease indication should not be stretched into broader claims
Internal projections suggest that annual approved claim costs for GLP-1 weight loss will eclipse $100 million for 2024 and grow to more than $170 million in 2025 for this market segment
Toxicol In Vitro
Business Type Exporter, Manufacturer, Distributor, Supplier, Trading Company Employee Count 500 Establishment 1992 Working Days To Related Products Explore Related Categories More Products From This Seller Seller Details Dalian, Liaoning Manager Mr John Wang Address RM702, Unit 1, Building 21, Liuhe Road, Ganjingzi Dist, Dalian, Liaoning, 116091, China Report incorrect details